

Technology Advisory Committee B Interests Register

Topic: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]

Publication Date: 10th July 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rhiannon Owen	Committee B Member	Direct - Financial	Rhiannon has previously received consultancy fees from Cogentia Healthcare Ltd who are representing the company - this was for DOACs in Atrial Fibrillation. Her last engagement with Cogentia was 2021.	11/04/2024	It was agreed that Rhiannon's declaration would not prevent her from participating in the committee.
Anthony Bewley	Clinical Expert	Direct – financial and non-financial	Mr Bewley has the following interests: <ul style="list-style-type: none"> • Editor (Royalties) - Practical Psychodermatology (Wiley 2014) • Ad Hoc consultancy (personal financial benefit) for Abbvie, Almirall, Bristol Myers Squibb, Beiersdorf, Celgene, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB • Immediate Past President ESDaP (www.psychodermatology.net) 	11/04/2024	It was agreed that Mr Bewley's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rhiannon Owen	Committee B Member	Direct - Financial	Rhiannon has previously received consultancy fees from Cogentia Healthcare Ltd who are representing the company - this was for DOACs in Atrial Fibrillation. Her last engagement with Cogentia was 2021.	11/04/2024	It was agreed that Rhiannon's declaration would not prevent her from participating in the committee.
			<ul style="list-style-type: none"> • Advisory roles to patient advocacy groups for Psoriasis Association, Changing Faces, ISG, NES • Recent Travel Grant to attend conferences from Janssen, Leo, Almirall, UCB 		
Richard Weller	Clinical Expert	Direct – financial	Mr Weller has served on an advisory board to Almirall in September 2023. This was remunerated (£300 per hour) and concerned the results of trials on Lebrikizumab.	11/04/2024	It was agreed that Mr Weller's declaration would not prevent him from providing expert advice to the committee.
Richard Weller	Clinical Expert	Indirect	Mr Weller was invited speaker at a dermatology education event for Almirall in Barcelona in 2016. His talk was about an unrelated subject to the current NICE application	11/04/2024	It was agreed that Mr Weller's declaration would not prevent him from providing expert advice to the committee.

